| Name | Title | Contact Details |
|---|
Headquartered in Roxboro, N.C., Open Book Extracts is a cGMP-certified manufacturer of premium plant-based cannabinoid products, aiming to be the industry`s true north by delivering premium products, exceptional service, and industry-leading transparency. With control of the entire supply chain, a state-of-the-art extraction campus near North Carolina`s Research Triangle, proprietary refinement and conversion methods backed by a growing IP portfolio, and a team of PhD chemists and seasoned business leaders, OBX is the trusted partner for global brands seeking to enter the marketplace. OBX Asia, with its headquarters in Hong Kong, provides strategic guidance and on-the-ground support for our Asia customers. OBX`s cGMP-certified productions operations are led by a seasoned science team, including a PhD food scientist from Cornell, a PhD organic chemist from the University of Nevada, and two masters chemists with pharmaceutical backgrounds, including a quality control director who joined OBX after a 15-year career as an analytical chemist at GlaxoSmithKline. OBX offers one of the largest portfolios of cannabinoid isolates at 99%+ purity, including CBD, CBG, CBN, CBC, and THCV, as well as formulation services and turnkey finished good manufacturing including edibles, softgels, tablets, tinctures, pet products, and topical products.
Janet, Jenner, & Suggs LLC is a Pikesville, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
BDM Information Systems Ltd. is a Saskatoon, SK-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
CliniQAl Consult Corporation is a North York, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs. FibroGen’s research team is committed to discovering novel therapies in areas of major unmet medical need. Our goal is to continue to provide pipeline candidates supported by rigorous data in well-characterized therapeutic settings. All of FibroGen`s therapeutic candidates have been internally developed based on FibroGen`s pioneering research in two important areas of biology, hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF).